Restoration of frontal activation during a treatment with quetiapine: an fMRI study of blunted affect in schizophrenia

Prog Neuropsychopharmacol Biol Psychiatry. 2005 Jan;29(1):21-6. doi: 10.1016/j.pnpbp.2004.08.015. Epub 2004 Nov 5.

Abstract

This study investigated changes in cerebral activation related to emotion processing in schizophrenia patients with blunted or flat affect (FA+) during treatment with quetiapine. Using functional magnetic resonance imaging (fMRI), brain activation in 12 FA+ schizophrenia patients during passive viewing of sad film excerpts was studied before and after a median of 5.5-months treatment with quetiapine. Random-effects 'paired sample t-test' analyses of brain activation before quetiapine (contrast=sad-neutral, before-after) revealed significant activation in the brainstem (pons, medulla). After quetiapine, the same contrast showed significant prefrontal activation (BA 9, 10 and 11). Activation of key prefrontal areas involved in emotion processing and significant symptoms improvement as measured by the subjective rating scale and PANSS suggests the potential effect of quetiapine in improving blunted affect related symptoms (i.e., passive withdrawal, emotional withdrawal, social avoidance) in schizophrenia.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Affect / drug effects
  • Affect / physiology*
  • Antipsychotic Agents / therapeutic use*
  • Dibenzothiazepines / therapeutic use*
  • Echo-Planar Imaging
  • Emotions / physiology
  • Female
  • Frontal Lobe / physiopathology*
  • Humans
  • Magnetic Resonance Imaging
  • Male
  • Psychiatric Status Rating Scales
  • Quetiapine Fumarate
  • Schizophrenia / drug therapy*
  • Schizophrenia / physiopathology*
  • Schizophrenic Psychology*

Substances

  • Antipsychotic Agents
  • Dibenzothiazepines
  • Quetiapine Fumarate